We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-20.31%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$268M
AUM Growth
-$125M
Cap. Flow
-$27.2M
Cap. Flow %
-10.13%
Top 10 Hldgs %
57.14%
Holding
61
New
14
Increased
11
Reduced
11
Closed
14

Top Buys

Rank Stock Value
1
AVTX icon
Avalo Therapeutics
AVTX
+$8.46M
2
EPZM
Epizyme, Inc
EPZM
+$7.06M
3
IMGN
Immunogen Inc
IMGN
+$6.2M
4
ABEO icon
Abeona Therapeutics
ABEO
+$3.93M
5
AIMT
Aimmune Therapeutics
AIMT
+$3.88M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$10M
2
AMAG
AMAG Pharmaceuticals
AMAG
+$8.4M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$7.01M
4
AMRN
Amarin Corp
AMRN
+$6.38M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.11M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDXS icon
1
Codexis
CDXS
$182M
$29.2M 10.91%
1,750,000
– –
AXGN icon
2
Axogen
AXGN
$2.78B
$26.6M 9.91%
1,300,000
– –
LOXO
3
DELISTED
Loxo Oncology, Inc
LOXO
$24.5M 9.15%
175,000
– –
AMRN
4
Amarin Corp
AMRN
$297M
$17M 6.35%
62,500
-17,500
-22% -$6.38M
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$16.2M 6.04%
300,000
– –
HROW icon
6
Harrow
HROW
$1.44B
$9.8M 3.66%
1,722,000
+102,000
+6% +$437K
KYNB
7
Kyntra Bio
KYNB
$32.4M
$9.26M 3.45%
8,000
– –
DCPH
8
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$7.14M 2.66%
340,000
-80,000
-19% -$1.97M
EPZM
9
DELISTED
Epizyme, Inc
EPZM
$6.93M 2.59%
1,125,000
+925,000
+463% +$7.06M
PTCT icon
10
PTC Therapeutics
PTCT
$5.99B
$6.52M 2.43%
190,000
+10,000
+6% +$360K
XNCR icon
11
Xencor
XNCR
$2.15B
$6.51M 2.43%
180,000
– –
VKTX icon
12
Viking Therapeutics
VKTX
$3.95B
$6.31M 2.36%
825,000
– –
SBBP
13
DELISTED
Strongbridge Biopharma plc.
SBBP
$6.23M 2.32%
1,390,000
-340,000
-20% -$1.66M
AVTX icon
14
Avalo Therapeutics
AVTX
$1.08B
$6.21M 2.32%
+759
New +$8.46M
FENC icon
15
Fennec Pharmaceuticals
FENC
$413M
$5.74M 2.14%
900,000
-75,000
-8% -$524K
SGMO
16
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.74M 2.14%
500,000
+10,000
+2% +$124K
CBAY
17
DELISTED
Cymabay Therapeutics
CBAY
$5.71M 2.13%
725,000
+26,900
+4% +$256K
PTE
18
DELISTED
PolarityTE, Inc. Common Stock
PTE
$5.4M 2.01%
16,000
-14,600
-48% -$5.28M
BOLD
19
DELISTED
Audentes Therapeutics, Inc
BOLD
$5.33M 1.99%
250,000
+25,000
+11% +$645K
CMRX
20
DELISTED
Chimerix, Inc.
CMRX
$5.19M 1.94%
2,020,000
+835,000
+70% +$2.8M
XOMA
21
DELISTED
Xoma
XOMA
$5.06M 1.89%
400,000
+80,000
+25% +$1.14M
IMGN
22
DELISTED
Immunogen Inc
IMGN
$4.9M 1.83%
+1,021,000
New +$6.2M
APLS
23
DELISTED
Apellis Pharmaceuticals
APLS
$3.63M 1.35%
275,000
-100,000
-27% -$1.53M
AIMT
24
DELISTED
Aimmune Therapeutics
AIMT
$3.59M 1.34%
+150,000
New +$3.88M
ABEO icon
25
Abeona Therapeutics
ABEO
$345M
$3.21M 1.2%
+18,000
New +$3.93M
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2018 Portfolio in Review

As of Q4 2018, Opaleye Management held 61 positions worth $268M, down 32% from $393M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Opaleye Management withdrew a net $27.2M in Q4 2018, closing 14 positions and reducing 11 holdings. Its most notable exit was Agios Pharmaceuticals, an estimated $10M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Opaleye Management opened a new position in Avalo Therapeutics worth $6.21M.

  • Opaleye Management's largest Q4 2018 buy was Avalo Therapeutics: 759 shares worth $6.21M.
  • Opaleye Management added most to Epizyme, Inc in Q4 2018, an estimated $7.06M increase.
  • Opaleye Management's biggest Q4 2018 reduction was Amarin Corp, cutting an estimated $6.38M.
  • Opaleye Management fully exited Agios Pharmaceuticals in Q4 2018, selling an estimated $10M.
  • Opaleye Management's ten largest holdings make up 57% of its $268M portfolio in Q4 2018.
  • Opaleye Management opened 14 new positions and closed 14 in Q4 2018.
  • Opaleye Management's portfolio value fell 32% quarter-over-quarter to $268M.

Based on Opaleye Management's 13F filing for Q4 2018, filed 14 Feb 2019.